title: Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers.
abstract: Treatment of hidradenitis suppurativa (HS) is often unsatisfactory. The efficacy of infliximab for treatment of the disease has been suggested. The main objective of this study was to evaluate the efficacy and side-effects of infliximab in the treatment of moderate to severe HS, resistant to local and systemic treatments. The secondary objective was to determine whether inflammation blood test results were changed. A retrospective monocentric study of all the patients seen consecutively for HS and treated with infliximab was performed. A median of six intravenous infusions (range 3-19) were performed. The end-points were self-improvement of HS (globally and in terms of pain, seeping and quality of life). The condition of six of seven patients improved (by nearly 50%) and none was aggravated. Adverse effects occurred in two patients; eczematous eruption in one case and cervical abscess in another case. We found no significant changes in inflammatory blood marker values. In conclusion, infliximab therapy was shown to be efficient and well tolerated in six of seven patients with HS resistant to previous therapy in our series. This was in agreement with pre-existing literature showing that 52 of 60 patients (87%) were improved after infliximab therapy.
authors.affiliation: Department of Dermatology, University Francois Rabelais Tours CHRU Tours, Tours, France. maiadelage@hotmail.com
authors.forename: Maïa
authors.initials: M
authors.lastname: Delage
authors.forename: Mahtab
authors.initials: M
authors.lastname: Samimi
authors.forename: Michaël
authors.initials: M
authors.lastname: Atlan
authors.forename: Laurent
authors.initials: L
authors.lastname: Machet
authors.forename: Gerárd
authors.initials: G
authors.lastname: Lorette
authors.forename: Annabel
authors.initials: A
authors.lastname: Maruani
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D003875:Drug Eruptions; D005260:Female; D017497:Hidradenitis Suppurativa / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D010146:Pain; D011788:Quality of Life; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D002097:C-Reactive Protein; D000069285:Infliximab